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Abstract
Hydroxycinnamic acid derivatives are important class of polyphenolic compounds originated from the Mavolanate-
Shikimate biosynthesis pathways in plants. Several simple phenolic compounds such as cinnamic acid, p-coumaric
acid, ferulic acid, caffeic acid, chlorgenic acid, and rosmarinic acid belong to this class. These phenolic compounds
possess potent antioxidant and anti-inflammatory properties. These compounds were also showed potential
therapeutic benefit in experimental diabetes and hyperlipidemia. Recent evidences also suggest that they may serve as
valuable molecule for the treatment of obesity related health complications. In adipose tissues, hydroxycinnamic acid
derivatives inhibit macrophage infiltration and nuclear factor κB (NF-κB) activation in obese animals.
Hydroxycinnamic acid derivatives also reduce the expression of the potent proinflammatory adipokines tumor
necrosis factor-α (TNFα), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor
type-1 (PAI-1), and they increase the secretion of an anti-inflammatory agent adiponectin from adipocytes.
Furthermore, hydroxycinnamic acid derivatives also prevent adipocyte differentiation and lower lipid profile in
experimental animals. Through these diverse mechanisms hydroxycinnamic acid derivatives reduce obesity and
curtail associated adverse health complications.
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Background
Metabolic syndrome is a cluster of non-communicable
diseases includes central obesity, diabetes, insulin resist-
ance, hypertension and dyslipidemia. Prevalence of obes-
ity and diabetes are increasing day by day among
children, young and elderly populations both in devel-
oped and developing countries [1–3]. A sedentary nature
of jobs and high calorie diet mainly western style diet
are the main causes of developing obesity and diabetes,
consequently metabolic syndrome [1, 4]. Ever increas-
ing obese and diabetes population are causing serious
problems for the management of health sector as well
as increasing personal health risks [4]. Recent evidence
also suggests that increased body fat mass causes car-
diovascular diseases and increases morbidity and mor-
tality in human [5, 6]. Dietary modification, for
example decreasing the intake of high fat and high
carbohydrate could be a possible way of reducing the
risk of fat accumulation in the body. In addition, several
dietary approaches such as Mediterranean diet or diet
containing high amount of fibres, fruits and vegetables
would be valuable for the prevention of hypertension,
diabetes, dyslipidemia and obesity [7, 8]. Mediterranean
diet or fruits and vegetables possess large amount of
phenolic or polyphenolic compounds. It is now widely
recognized that, phenolic or polyphenolic compounds
are strong antioxidant substances and showed anti-
inflammatory properties [9, 10]. Some of them are also
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effective against diabetes, insulin resistance and dyslip-
idemia [11–15]. Many of them also prevent hyperten-
sion and cardiovascular diseases [16]. All these
biological activities are mainly regulated by phenolic
acid’s ability to scavenge free radicals generated due to
excess nutrition supply to the tissues in obesity, or they
may regulate the energy homeostasis and inflammatory
pathways. This work will thus review the potential
health benefit of hydroxycinnamic acid derivatives in
obesity and metabolic syndrome and their possible
mechanism of action.
Obesity and energy homeostasis, mechanism of fat
metabolism
Obesity can be defined as the accumulation of excess fat
due to the increased energy intake and lack of energy ex-
penditure. However, World Health Organization uses
Body Mass Index (BMI) as a parameter for defining
obesity. According to WHO, BMI >30 is considered as
moderately obese and BMI > 35 is considered as severely
obese in human [17]. Global obesity in young to adult
population is increasing tremendously in recent years
[18, 19]. Lack of physical movements, sedentary nature
of work and consumption of diet containing high carbo-
hydrate and high fat are responsible for the development
of obesity [20]. Thus, increased energy expenditure
would be a contributing factor to control and manage
obesity and related pathophysiological conditions. Mito-
chondrial biogenesis are the major pathways in various
cell types like, liver, adipose tissue, skeletal muscle etc.
to increase ATP production and energy expenditure. De-
creased mitochondrial function was observed in obesity
and metabolic disorder [21–23]. In obese condition,
abundance of fuel supply e.g., fatty acid and glucose
overwhelm the mitochondrial electron transport chain
and increased the superoxide production [24–27].
Mitochondrial biogeneses are regulated via several tran-
scriptional regulatory factors like AMPK, PPAR- γ and
PGC-1α [28, 29]. AMPK regulated PPAR-γ and PGC-
1α activation stimulated most of the transcriptional sig-
nal to increase fatty acid oxidation and mitochondrial
function [30–32].
AMPK
AMP-activated protein kinase (AMPK) is a cellular fuel
gauge, maintaining intracellular energy balance in mam-
malian cells [33]. AMPK signalling pathway is activated
by elevation of the AMP/ATP ratio due to the decreased
ATP synthesis by mitochondria or by increased energy
(ATP) expenditure [33]. Glucose deprivation, hypoxia or
ischaemia, or metabolic poisons are few factors which
may inhibit glycolysis, tricarboxylic acid cycle or oxida-
tive phosphorylation and disturb energy balance by
interfering with ATP synthesis, which may trigger
activation of AMPK signalling [34]. AMPK activation is
necessary for the transcriptional regulation of energy de-
mand. Mice expressing a dominant-negative form of
AMPK failed to increase mitochondrial biogenesis in re-
sponse to energy deprivation in skeletal muscles [35]. In
contrast, lipid oxidation and mitochondrial activity was
increased in mice over expressing the phosphorylated
AMPK [36, 37]. Several ligands such as thiazolidine-
diones (for example, rosiglitazone) and biguanides (met-
formin) both activates AMPK [38]. Thiazolidinediones
and biguanides inhibits complex I of the mitochondrial
respiratory chain and elevates cellular AMP/ATP ratios
[39]. Furthermore, mice fed with AMPK agonists in-
creased oxidative gene expression, enhanced endurance
capacity and gave protection against metabolic disease
[40, 41]. AMPK can also be activated by metabolic
stresses such as muscle contraction or hypoxia, and
modulated by hormones and cytokines affecting whole-
body energy balance such as leptin, adiponectin, resistin,
ghrelin and cannabinoids [33].
PPAR- γ
AMPK activation increased the fatty acid oxidation
through activating the PPAR-γ and PGC-1α [42]. Peroxi-
some proliferator activator protein-γ (PPAR- γ) is highly
expressed in adipose tissues [43]. The expression of
PPARγ in liver is very low compared to the level present
in adipose tissue [43–45]. The actions of PPAR-γ are
mediated by two protein isoforms, PPARγ1 and PPARγ2
[46]. PPARγ1 is widely expressed while PPARγ2 is re-
stricted to the adipose tissue only [46]. Fatty acids
binding activates PPAR-γ [46]. Activation of PPARγ is
necessary for adipocyte differentiation and fatty-acid
storage [43, 44]. PPAR-γ deficient mice are devoid of
adipose tissue and PPAR-γ +/− mice are characterized
by a decreased adipose tissue mass [47, 48]. PPAR-γ is
also important for anti-inflammatory pathways, lipid me-
tabolism and regulates genes taking part in the release,
transport and storage of fatty acids [49, 50]. Moreover,
PPARγ is also responsible for the improvement of insu-
lin resistance and plays an important role in glucose
homeostasis. Mice lacking PPARγ in fat, muscle,
or liver are predisposed to develop insulin resistance
[51–54] while mice with increased PPARγ activities are
protected from obesity-associated insulin resistance
[55]. PPARγ is a ligand activated protein, thiazolidine-
diones are considered as the activator of PPARγ [56].
However, thiazolidinediones are adipogenic and respon-
sible for moderate weight gain in patients taking thiazo-
lidinediones [50, 57].
PGC-1α
Peroxisome proliferator activator protein-γ co-activator-
1α (PGC-1α) is another regulator of lipid and glucose
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metabolism. AMPK regulates PGC-1α at both gene and
protein level [36]. PGC-1α directly co-activates multiple
transcriptional factors such as the PPARs or the thyroid
hormone receptor, glucocorticoid receptors and estrogen
receptors [29, 58]. PGC-1α also increases mitochondrial
biogenesis and respiration rates, as well as the uptake
and utilization of substrates for energy production [59].
In brown adipose tissue (BAT), cold induces PGC-1α
protein expression that controls adaptive thermogenesis
[59]. Furthermore, fasting induces hepatic PGC-1α ex-
pression and increases gluconeogenesis, whereas in
skeletal and cardiac muscle, exercise increases PGC-1α
mediated mitochondrial biogenesis and respiration [60].
Phenolic compound resveratrol increased the PGC-1α
activity and increased running time and consumption of
oxygen in muscle fibers in mice [61]. Moreover, resvera-
trol increased insulin sensitivity, reduced insulin-like
growth factor-1 (IGF-I) levels, increased AMP-activated
protein kinase (AMPK) and peroxisome proliferator-
activated receptor-gamma co-activator-1α (PGC-1α) ac-
tivity, increased mitochondrial number, and improved
motor function in middle-aged mice fed a high-calorie
diet [62].
Inflammation and obesity
Inflammation is a protective response mechanism for
tissue injury. Both acute and chronic inflammatory re-
sponses are responsible for the development of diabetes
and insulin resistance [63, 64]. Recent research findings
suggest that chronic low grade inflammation is devel-
oped in obese individuals and triggers adipocyte dys-
function [65]. Moreover, adipose tissues are playing a
major role in secreting pro-inflammatory and inflamma-
tory cytokines during obesity [66]. Pathologic growth of
adipocyte houses many of inflammatory cytokines like
TNF-alpha and IL-6 [67]. Inputs into this inflammatory
response further stimulate ER stress, adipose tissue hyp-
oxia, and adipocyte death [68–70]. Macrophage numbers
in adipose tissues are also increased with obesity where
they mainly scavenge the dead adipocytes [71, 72]. Mac-
rophages are also responsible for the cytokine produc-
tion in obese adipose tissues [73].
Hydroxycinnamic acid derivatives overview
Hydroxycinnamic acid derivatives (Fig. 1) comprise a
large group of simple phenolic acids, found mainly in ce-
reals, fruits and vegetables. A review has been published
recently describing the occurrence, biosynthesis, and
pharmacokinetics of hydroxycinnamic acid derivatives
[74]. Ferulic acid, caffeic acid, p-coumaric acid, chlor-
genic acid, sinapic acid, curcumin, and rosmarinic acid
belongs to this important phenolic acid group. Hydroxy-
cinnamic acids are abundant in fruits, vegetables and ce-
reals and seeds of fruits [74]. In plant, hydroxycinnamic
acid derivatives are synthesized by following the mavolo-
nate and shikimate pathways where phenylalanine and
tyrosine are two starter precursor molecules [74, 75].
Following several intermediate enzymatic process, shi-
kimate pathways produced cinnamic acid, p-coumaric
acid, caffeic acid, ferulic acid, sinapic acid to various
complex lignin molecules [74, 75]. Hydroxycinnamic
acid derivatives are also serving as precursor molecules
for the stilbenes, chalcons, flavonoids, lignans, and an-
thocyanins [74].
Fig. 1 Structures of hydroxyl cinnamic acid derivatives. Cinnamic acid, p-caumaric acid, ferulic acid, caffeic acid, chlorgenic acid, rosemarinic acid
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HCAs are absorbed easily from the stomach and intes-
tine depending on their structure and compared to other
complex phenolic compounds [76]. Ferulic acid and p-
coumaric acid are also absorbed from intestine, jejunum,
ileum and colon of rats [74]. However, chlorgenic acid,
ester of caffeic and quinic acid, first hydrolysed and free
caffeic acid is absorbed from the intestine [76]. In Caco-
2 cell monolayers, caffeic acid demonstrated that mono-
carboxylic acid transporters (MCTs), a transport system
present across the intestinal epithelial cells, may be in-
volved in the absorption process [77, 78]. p-Coumaric
acid and ferulic acid also followed the same monocar-
boxylic acid transporter (MCT) system to cross the in-
testinal epithelium [77, 78]. However, passive diffusion
mechanism is also important and not ignored for the ab-
sorption of ferulic acid in the stomach and Caco-2 cells
[75, 79]. In addition, involvement of a Na+-dependent,
carrier-mediated transport process are also involved in
the uptake of cinnamic acid and ferulic acid across the
brush border membrane of rat jejunum [80]. Bioavail-
ability of cinnamic acid derivatives are reviewed recently
[74, 76]. Various cinnamic acid derivatives can be found
in plasma immediately after the oral administration and
may show various health benefit in different diseases
(Fig. 2).
Effect of Hydroxycinnamic acid derivatives on
various parameters of Metabolic syndrome
Effect of hydroxycinnamic acid derivatives in
Inflammation
Hydroxycinnamic acid derivatives showed anti-inflam-
matory properties both in vitro and in vivo [81]. Ferulic
acid prevented the production of TNF-alpha and de-
creased Macrophage inflammatory protein-2 (MIP-2)
levels in lipopolysaccharide (LPS)-stimulated RAW264.7
cells [82]. The transcription factor nuclear factor kappa B
(NF-κB) plays a critical role in stress, immune, and inflam-
matory responses. Ferulic acid in cereals inhibits NF-kB
activation [83]. Salt of ferulic acid, ferulate, exhibited anti-
oxidant action by maintaining redox regulation, suppress-
ing NF-κB activation and modulating the expression of
NF-κB-induced, proinflammatory COX-2, iNOS, VCAM-
1 and ICAM-1 in aged Sprague–Dawley rats [84]. NF-kB
suppression by ferulate is mediated via suppressing the ac-
tivation of NIK/IKK and MAPKs [84].
p-Coumaric acid prevented the increased cell-mediated
immune responses and macrophage phagocytic index in
rats [85].p- Coumaric acid also decrease in the expression
of inflammatory mediator TNF-α and circulating immune
complexes in adjuvant induced arthritic rats [85]. p-Cou-
maric acid also inhibited the TNF-α-induced changes in
levels of monocyte chemoattractant protein-1 (MCP-1),
plasminogen activator inhibitor-1 (PAI-1), and intracellu-
lar reactive oxygen species (ROS) in 3 T3-L1 adipocytes
[86]. Furthermore, p-coumaric acid increased the secre-
tion and concentration of adiponectin, superoxide dismut-
ase (SOD), glutathione (GSH), glutathione peroxidase
(GPx), and glutathione S-transferase (GST) in TNF-α-
treated 3 T3-L1 adipocytes [86].
Caffeic acid phenetyl ester (CAPE) non-selectively
inhibited the activities of baculovirus-expressed hCOX-
1 and hCOX-2 enzymes and inhibits prostaglandin syn-
thesis and COX 2 in the rat carrageenan air pouch
model of inflammation [87]. Caffeic acid and some of
its derivatives such as caffeic acid phenetyl ester
(CAPE) and octyl caffeate showed anti-inflammatory
activity both in vitro and in vivo [88]. Caffeic acid de-
rivatives suppressed the iNOS expression and pre-
vented the production of NO from RAW macrophage
cells. Moreover, butyl, octyl and CAPE derivatives of
caffeic acid inhibited carrageenan-induced paw edema
and prevented the increase in IL-1β levels in the mouse
Fig. 2 Health benefit of cinnamic acid derivatives in various diseases
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paw [88]. Butyl, octyl and CAPE derivatives also pre-
vented carrageenan-induced neutrophil influx in the
mouse paw [88]. Caffeic acid supplementation reduced
the inflammatory cytokines interleukin (IL)-beta, IL-6,
tumor necrosis factor (TNF)-alpha and monocyte
chemoattractant protein (MCP)-1 concentration in dia-
betic mice [16].
Chlorogenic acid, the ester of caffeic acid with quinic
acid blocked UVB- or TPA-induced transactivation of
AP-1 and NF-κB in JB6 P+ cells [89]. CGA inhibited
lipopolysaccharide (LPS)-induced inflammatory response
in RAW 264.7 cells mediated by decreasing cyclooxy-
genase (COX-2) at protein and mRNA levels and de-
creased the secretion of prostaglandin E2 (PGE2) [90].
Table 1 Lipid lowering effect of hydroxycinnamic acid derivatives
Derivatives Model Experimental outcome Reference
Cinnamic acid High Cholesterol fed rats (Cinnamic acid (0.02 %, w/w) - Inhibited hepatic HMG-CoA reductase and ACAT
activity.
- Reduced the elevated AST and AST concentration in
plasma.
- Lowered plasma and liver triglycerides and cholesterol
concentrations.
- Improved antioxidant ezymes activities in erythrocytes
and liver.
[96]
Cinnamic acid (30 mg/kg/day) for 7 weeks - The administration of CA to HFD-fed rats reduced the
body weight gain
- Reduced serum lipid profile and
- Reverted back near to normal of lipase and ACE
enzymes activities
[122]
HFD diet fed Male Wistar rats
Ferulic acid C57BL/6 mice fed with high fat diet. - Lowered liver and plasma cholesterol by reducing
fatty acid synthase and glucose 6 phosphate
dehydrogenase
[97]
Golden syrian hamsters (chow-based
hypercholesterolemic diet (HCD) containing 10 %
coconut oil and 0.1 % cholesterol for 2 weeks)
- Lowered plasma plasma lipid and lipoprotein
cholesterol concentrations.
- Preserved the antioxidant status by preserving higher
amount of Vitamin E in plasma.
[98]
Stroke-prone spontaneously hypertensive rats (SHRSP) - Plasma total cholesterol and triglyceride levels were
lower after 2 h administration.
- The mRNA expression of genes involved in lipid and
drug metabolism was downregulated
[99]
Apolipoprotein E-deficient (apo E−/−) mice fed Western - Lowered the Concentrations of total cholesterol
(total-C), apolipoprotein B (apo B) in the plasma and
epididymal adipose tissue wet weight
- Lowered hepatic ACAT and HMG-CoA reductase were
only significantly.
[101]
Male apo E−/− mice - Lowered The hepatic and erythrocyte thiobarbituric
acid-reactive substances levels.
- Lowered the plasma total cholesterol concentration
accompanied with a decreased hepatic acyl-coenzyme
A: cholesterol acyltransferase activity.
[100]
Streptozotocin induced diabetes rat - Reduced the elevated plasma lipid and blood glucose
levels
[102]
Caffeic acid High fat diet in mice (30 mg/kg of CAPE) - Reduced plasma cholesterol and triglycerides.
- Amelioration in hepatic steatosis.
- Increase in glucose sensitivity by improving
phosphorylation of the insulin receptor substrate-2 and
Akt phosphorylation.
- Reduced the induction of the inflammatory pathway,
c-jun-N- terminal kinase, the nuclear factor kappa B,
and cyclooxygenase-2 expression.
[117]
Chlorogenic acid ICR mice fed with high fat diet. - Lowered plasma cholesterol by reducing the activity
of fatty acid synthase and HMG-CoA reductase and
increased the fatty acid beta oxidation.
[15]
Fa/fa Zucker Rats - Lowered plasma fasting cholesterol and triglycerides [103]
Streptozotocin (STZ)–nicotinamide (NA)-induced type 2
diabetic rats. (CGA 5 mg/kg)
- Lowered the plasma lipid; cholesterol, free faty acids
and triglycerides.
- Lowered HMG-CoA reductase activity in liver and
increased LPL activity in plasma.
[104]
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Table 2 Effect of hydroxycinnamic acid derivatives on obesity and adipocyte dysfunction
Derivatives Model Experimental outcome Reference
Cinnamic acid 3 T3-L1 adipocytes - Stimulated the secretion of adiponectin and the phosphorylation
of AMPK in 3 T3-L1 adipocytes and therefore improves insulin
sensitivity
[123]
- Cinnamic acid (30 mg/kg/day) for 7 weeks - The administration of CA to HFD-fed rats reduced the body
weight gain.
[122]
- HFD diet fed Male Wistar rats
Coumaric acid 3 T3-L1 adipocytes - Inhibition of adipogenesis in 3 T3-L1 adipocytes. [124]
- o-coumaric acid inhibited GPDH activity and the expression of
PPARγ, C/EBPα and leptin and then up-regulated expression of
adiponectin.
3 T3-L1 adipocytes - p-Coumaric acid inhibited TNF-α-induced changes in levels of
monocyte chemoattractant protein-1 (MCP-1), plasminogen
activator inhibitor-1 (PAI-1), and intracellular reactive oxygen species
(ROS) in 3 T3-L1 adipocytes.
[125]
- p-Coumaric acid increased the secretion of adiponectin,
superoxide dismutase (SOD), glutathione (GSH), glutathione
peroxidase (GPx), and glutathione S-transferase (GST) in TNF-α-
treated 3 T3-L1 adipocytes
Wistar rats fed a high fat diet.(100 mg/kg) - Decreased body weight, liver organ, and adipose tissue weights of
peritoneal and epididymal fat pads.
[12]
- Decreased hepatic triacylglycerol and cholesterol levels.
- Enhanced the levels of glutathione (GSH), GSH peroxidase (GPx),
GSH reductase (GRd), and GSH S-transferase (GST) in the hepatic
tissue
Ferulic acid high fat diet-induced obesity in mice - Oryzanol or ferulic acid significantly suppressed the weight gain of
the high fat diet-induced obesity in mice.
[97]
- Ferulic acid is more effectively suppressed the weight gain
compared to oryzanol.
Caffeic acid 3 T3-L1 adipocytes - Inhibitory effects on increased glycerol-3-phosphate dehydrogenase
(GPDH) activity and an increased insulin receptor substrate 1 (IRS-1).
[126]
- Reduced the levels of leptin, resistin, and tumor necrosis factor
(TNF)-alpha.
High-fat diet induced obese mice (0.02 % CFA
of diet (wt/wt) dose)
- Lowered body weight, visceral fat mass and plasma leptin and
insulin levels.
[15]
- Inhibited fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA
reductase and acyl-CoA:cholesterol acyltransferase activities.
- increased fatty acid β-oxidation activity and peroxisome
proliferator-activated receptors α expression in the liver
Chlorogenic acid High-fat diet induced obese mice (0.02 % CGA
of diet (wt/wt) dose)
- Lowered body weight, visceral fat mass and plasma leptin and
insulin levels.
[15]
- Inhibited fatty acidsynthase, 3-hydroxy-3-methylglutaryl CoA
reductase and acyl-CoA:cholesterol acyltransferase activities.
- Increased fatty acid β-oxidation activity and peroxisome
proliferator-activated receptors α expression in the liver.
Streptozotocin (STZ)–nicotinamide (NA)-
induced type 2 diabetic rats CGA (5 mg/kg b.w.)
- Decreased plasma and tissue triglycerides, free fatty acids. [104]
- Decreased the activity of HMG-CoA reductase.
- Prevents lipid accumulation in liver.
Insulin resistant (fa/fa) Zucker rats (infused
CGA 5 mg/Kg body weight/day)
- Fasting plasma cholesterol and triacylglycerols concentrations
were significantly decreased.
[103]
Golden hamsters (80 mg CGA/kg body weight
daily given peritonially)
- Lowered fasting serum triglyceride (TG), free fatty acid (FFA), total
cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high
density lipoprotein cholesterol (HDL-C), glucose (FSG), and insulin
(FSI).
[127]
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Chlorogenic acid also inhibited LPS induced inflamma-
tion of liver in mice and prevented the mRNA expres-
sion of toll-like receptor 4 (TLR4), TNF-α and NF-κB
p65 subunit [91].
Effect of hydroxycinnamic acid derivatives on lipid and
fat metabolism
Elevated plasma concentrations of total cholesterol (TC)
and low density lipoprotein (LDL) cholesterol (and/or
reduced high-density lipoprotein [HDL]) are commonly
seen in dyslipidemia and strongly associated with cardio-
vascular disease, peripheral vascular disease and stroke
[92]. High fat diet feeding in laboratory animals showed
dyslipidemic condition similar to human dyslipidemia.
Several plant based compounds e.g., plant stanols and
sterols, tea-based catechins and theaflavins showed im-
provement in lowering plasma lipid profiles; however
the clinical efficacy of many of these substances are not
well studied [93]. Most of the hydroxycinnamic acid de-
rivatives are effective against fat deposition and lowered
plasma lipid profile and increases fat metabolism in liver
(Table 1). Polyphenol rich red wine improved plasma
lipid profiles by increasing HDL cholesterol levels, im-
prove LDL oxidation [94] and improved the antioxidant
status by reducing the oxidative stress in patients [95].
Cinnamic acid derivative supplementation lowered
the plasma and liver triglycerides and cholesterol con-
centrations in high cholesterol fed rats [96]. Ferulic acid
supplementation also lowered plasma lipid and choles-
terol concentrations in various model of dyslipidemia
such as C57BL/6 mice fed with high fat diet [97],
Golden syrian hamsters fed with chow-based hypercho-
lesterolemic diet [98], stroke-prone spontaneously
hypertensive rats [99], apolipoprotein E-deficient (apo
E−/−) mice fed Western diet [100, 101] and in strepto-
zotocin induced diabetes rats [102]. Chlorogenic acid
infusion in diabetic Zucker rats lowered the fasting
plasma cholesterol and triacylglycerol concentrations
significantly [103]. Chlorogenic acid also lowered the
plasma cholesterol in ICR mice fed with high fat diet
[15] and lipid, free fatty acids and triglycerides in Strep-
tozotocin (STZ)–nicotinamide (NA)-induced type 2
diabetic rats [104].
Cholesterol lowering effect is attributed to the inhibition
of the cholesterol synthesis and utilization of the free fatty
acids in liver. HMG-CoA reductase is the rate regulating
enzymes found in liver which is responsible for the choles-
terol biosynthesis. Several statins selectively inhibited the
HMG-CoA reductase in liver and lowered plasma choles-
terol in hyperlipidemic patients [105, 106]. Hepatic ACAT
is other type of enzymes that increased the utilization of
fatty acid for cholesterol biosynthesis. Cinnamic acid de-
rivatives such as cinnamic acid, ferulic acid, chlorgenic
acid reduced the HMG-CoA reductase and ACAT activity
in experimental animals [96, 101, 15, 104]. Ferulic acid de-
creased hepatic acyl-coenzyme A: cholesterol acyltransfer-
ase activity [100, 101] and down regulates the genes
involved in lipid metabolism [99]. Moreover, Chlorgenic
acid increased beta-oxidation and lypolitic lipase activity
in diabetic animal [15, 104].
Effect of hydroxycinnamic acid derivatives on body
weight and obesity
Hydroxycinnamic acids are also effective against body
weight gain, fat deposition and dysfunction of the adipo-
cytes due to high fat diet feeding in animal model
(Table 2). Adipocyte proliferation and differentiation plays
critical role on adipose tissue deposition and dysfunction.
3 T3-L1 preadipocytes are excellent cell lines for studying
the anti-obesity effect of various therapeutic agents.
Addition of phenolic acids to the growth medium de-
creased the cell population of 3 T3-L1 preadipocytes in
vitro [107]. Chlorogenic acid, o-coumaric acid, and m-
coumaric acid caused cell cycle arrest in the G1 phase in
3 T3-L1 preadipocytes [107]. Ferulic acid prevented the
body weight gain in high fat diet fed mice and decreased
the plasma and liver lipids, triglycerides and total choles-
terol [97]. Ferulic acid also decreased the activity of hep-
atic lipogenic enzymes, such as G6PD, ME, and FAS
which are responsible for the cholesterol and fatty acid
synthesis [97]. Chlorogenic acid showed anti-obesity effect
on mice fed with a high fat diet [15]. Chlorogenic acid also
lowered the visceral fat mass and plasma leptin and insu-
lin levels compared to the high-fat control group [15].
Caffeic acid and chlorogenic acid significantly inhibited
fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA
Table 2 Effect of hydroxycinnamic acid derivatives on obesity and adipocyte dysfunction (Continued)
- Increased hepatic lipase (HL), lower contents of TG and FFA in
liver and lower activity of lipoprotein lipase (LPL) in skeletal muscle.
- Elevated the expression level of mRNA and protein expression in
hepatic PPAR-α.
High Cholesterol diet fed Sprague–Dawley
rats (1 or 10 mg/kg/day p.o. CGA)
- Lowered total cholesterol, triglycerides, high-density lipoprotein
and low-density lipoprotein.
[128]
- Up-regulated of peroxisome proliferation-activated receptor α
mRNA in liver.
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Table 3 Effect of hydroxycinnamic acid derivatives on diabetes
Derivatives Model Experimental outcome Reference
Cinnamic acid TNF-α-treated insulin-resistant mouse FL83B
hepatocytes.
- Increased expression of glycogen synthase, whereas the
expression of glycogen synthase kinase and phosphorylation of
glycogen synthase at Ser641 in insulin-resistant mouse hepatocytes
was decreased.
[111]
STZ-induced diabetic Wistar Albino rats - Improved glucose tolerance and carbohydrate metabolizing
enzymes,
[13]
Ferulic acid STZ-induced diabetic mice (0.01 and 0.1 % FA
of diet)
- Decreased elevated blood glucose level [14]
KK-Ay mice (0.05 % FA of Diet) - Suppress blood glucose level [14]
C57BL/KsJ db/db mice - Decreased blood glucose level by increasing glycogen synthesis.
Increased glucokinase activity.
[112]
Streptozotocin induced diabetes rats - Prevents lipid peroxidation and improved the antioxidant enzymes
such as glutathione peroxidase (GPx), superoxide dismutase (SOD)
and catalase (CAT)
[114]
Otsuka Long-Evans Tokushima Fatty (OLETF)
diabetic rats (0.2 % FA in diet)
- Improved
Male C57BL/6 N mice (0.5 % FA of diet) - Lower blood glucose level and glucose-6-phosphatase (G6pase)
and phosphoenolpyruvate carboxykinase (PEPCK) activities.
[113]
Stroke-prone spontaneously hypertensive rats
(SHRsp) (0 · 01 g/kg FA of diet)
- Improved hypertension as well as glucose tolerance, plasma nitric
oxide (NOx). Also increased several mRNA expressions of metabolic
parameters involved in glucose and lipid metabolisms
[129]
- high-fat and fructose-induced type 2 dia-
betic adult male rats
- FA treatment to diabetic animals restored blood glucose, serum
insulin, glucose tolerance, and insulin tolerance to normal range.
- Hepatic glycogen concentration, activity of glycogen synthase,
and glucokinase were significantly increased, whereas activity of
glycogen phosphorylase and enzymes of gluconeogenesis
(phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase)) were decreased in diabetic animals due to
FA treatment
[130]
- FA (50 mg/(kg body weight · day)(−1), orally)
for 30 days
- high-fat and fructose-induced type 2 dia-
betic adult male rats
- Authors suggested that FA treatment reduced the GLUT2
expression in diabetic animals by impairing the interaction between
these transcription factors (SREBP1c, HNF1α and HNF3β) and GLUT2
gene promoter.
[131]
- FA (50 mg/(kg body weight · day)(−1), orally)
for 30 days
Caffeic acid C57BL/KsJ-db/db mice - Reduction of the blood glucose and glycosylated hemoglobin
levels. Caffeic acid also markedly increased glucokinase activity and
its mRNA expression and glycogen content and simultaneously
lowered glucose-6-phosphatase and phosphoenolpyruvate
carboxykinase activities and their respective mRNA expressions,
accompanied by a reduction in the glucose transporter 2 expression
in the liver
[115]
Streptozotocin induced diabetes rats - Improved lipid peroxidation and antioxidant enzyme status in liver
of rats
[132]
Mouse liver FL83B cells - Tumor necrosis factor-α was used to induce insulin resistance. may
promote insulin receptor tyrosyl phosphorylation, up-regulate the
expression of insulin signal associated proteins, including insulin
receptor, phosphatidylinositol-3 kinase, glycogen synthase, and
glucose transporter-2, increase the uptake of glucose, and alleviate
insulin resistance
[118]
TNF-α-treated insulin-resistant mouse FL83B
hepatocytes.
- Increased expression of glycogen synthase, whereas the
expression of glycogen synthase kinase and phosphorylation of
glycogen synthase at Ser641 in insulin-resistant mouse hepatocytes
was decreased.
- Also suppressed the expression of hepatic nuclear
factor-4 and activity of phosphoenolpyruvate carboxykinase
[111]
High fat diet in male BLTW: CD1(ICR) mice - Improved the glucose intolearance and normalized plasma insulin,
adiponectin.
- also suppress TNF-alpha, PEPCK and increased GLUT4
[119]
L6-GLUT4myc cells - Increased glucose uptake and GLUT4 translocation to the cell
membrane of L6-GLUT4myc cells.
[120]
Alam et al. Nutrition & Metabolism  (2016) 13:27 Page 8 of 13
reductase and acyl-CoA:cholesterol acyltransferase activ-
ities, while they increased fatty acid β-oxidation activity
and peroxisome proliferator-activated receptors α expres-
sion in the liver compared to the high-fat group [15].
Effect of hydroxycinnamic acid derivatives on diabetes
and insulin resistance
Hyperglycemia and insulin resistance are commonly seen
in obesity [108–110]. Polyphenolic compounds showed
prevention of metabolic disorder associated with hyper-
glycemia and diabetes. The mechanisms behind these
benefits have multiple targets. Some molecules pre-
vented the beta cell destruction in pancreas thereby in-
creasing the insulin secretion. Others include inhibition
of carbohydrate digestive enzymes, increased glycogen
synthesis, increased glucose uptake in muscle tissues
and adipocytes by phosphorylation of AMPK and in-
creased GLUT4 content as well as increasing glucose
metabolism. Hydroxycinnamic acid derivatives also
showed considerable hypoglycaemic activities in experi-
mental condition (Table 3). Cinnamic acid improved
glucose intolerance and insulin resistance in STZ in-
duced diabetic rats [13]. Cinnamic acid also increased
the expression of glycogen synthase, whereas the ex-
pression of glycogen synthase kinase and phosphoryl-
ation of glycogen synthase at Ser641 in TNF-α-treated
insulin-resistant mouse hepatocytes was decreased
[111]. Rice bran fraction and ferulic acid reduced the
blood glucose concentrations and increased the insulin
in plasma of diabetic C57BL/KsJ db/db mice [112]. Glu-
cose lowering effect by ferulic acid was also seen in KK-Ay
mice [14] and STZ induced diabetic mice [14]. Ferulic acid
also increased glucokinase activity [112] and decreased
glucose-6-phosphatase (G6pase) and phosphoenolpyr-
uvate carboxykinase (PEPCK) activities in liver [113].
Moreover, ferulic acid prevented lipid peroxidation and
improved the antioxidant enzymes such as glutathione
peroxidase (GPx), superoxide dismutase (SOD) and cata-
lase (CAT) [114].
Caffeic acid has been studied extensively in experi-
mental diabetes and related complications. Caffeic acid
lowered blood glucose level in C57BL/KsJ-db/db mice
[115] and Streptozotocin (STZ)-induced diabetic rats
[116]. Caffeic acid also improved insulin level in plasma
of male Balb/cA mice [11] and improved glucose in-
tolerance in high fat diet fed male mice [117]. Caffeic
acid improved insulin resistance by promoting insulin
receptor tyrosyl phosphorylation, up-regulate the ex-
pression of insulin signal associated proteins, including
insulin receptor, phosphatidylinositol-3 kinase, glycogen
synthase, and glucose transporter-2, increase the uptake
of glucose in tumor necrosis factor-α induced insulin
resistant mouse liver FL83B cells [118]. Other studies
showed that caffeic acid decreased the inflammatory cy-
tokines [119] and reduced the induction of the inflam-
matory pathway, c-jun-N- terminal kinase, the nuclear
Table 3 Effect of hydroxycinnamic acid derivatives on diabetes (Continued)
- Increased phosphorylation of
AMPK and increased GLUT4 content
Streptozotocin (STZ)-induced diabetic rats - Phoshoenolpyruvate carboxykinase mRNA expression was
decreased.
- Decreased the fasting blood levels of glucose, alanine
aminotransferase, cholesterol, and triglyceride induced by diabetes.
- increased expressions of glucokinase and pyruvate kinase mRNAs
and increased the liver glycogen level.
[116]
Swiss mice fed high fat diet - Improved glucose intolerance in high fat diet fed mice.
- Improvement in insulin-stimulated phosphorylation of the insulin
receptor substrate-2, followed by an increase in Akt phosphorylation.
- Reduced the induction of the inflammatory pathway, c-jun-N-
terminal kinase, the nuclear factor kappa B, and cyclooxygenase-2
expression.
[117]
Male Sprague–Dawley rats - Increased the phosphorylation of AMPKα Thr172 in skeletal
muscle.
- AMPKα2 activity increased significantly, whereas AMPKα1
activity did not change.
[133]
Male Balb/cA mice (2.5 % CFA of Diet) - Increased plasma insulin and decreased blood glucose and plasma
HbA1c levels.
- Lowered renal levels of IL-6, IL-1b, tumor necrosis factor (TNF)-a
and monocyte chemoattractant protein 1 (MCP-1) and decreased
TNF alpha and MCP-1 mRNA expression.
[11]
Chlorogenic acid db/db mice - Improved the fasting blood glucose level.
- Stimulates glucose transport in skeletal muscle via the GLUT 4
translocation and phosphorylation of AMPK and Akt.
[121]
Male Sprague–Dawley rats (CGA (120 mg · kg–1) - Improved glucose metabolism as seen in decreased AUC. [134]
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factor kappa B, and cyclooxygenase-2 expression [11].
Furthermore, Caffeic acid increased increased phos-
phorylation of AMPKs and increased glucose uptake and
GLUT4 content in L6-GLUT4myc cells [120]. Chloro-
genic acid also follows the similar mechanism for improv-
ing insulin resistance and diabetes. Chlorogenic acid
stimulates glucose transport in skeletal muscle via the
GLUT 4 translocation and phosphorylation of AMPK and
Akt in db/db mice [121].
Conclusion
Recent research has provided the scientific benefit of
these phenolic acids and confirmed the important role
of phenolic acids in the prevention and treatment of
obesity, diabetes and associated disorders. Phenolic acids
could favourably affect most of the leading aspects of
obesity including diabetes, including insulin resistance,
hyperglycemia, hyperlipidemia, and adepocyte dysfunc-
tion and inflammation (Fig. 3). Despite the potential
benefits of these natural products in preclinical studies,
scanty literatures have been found on any beneficial ef-
fect from clinical trials of phenolic acids so far. Studies
are thus required in humans to confirm the potential
benefit of phenolic acids in limiting obesity and other as-
sociated disorders. Furthermore, multiple approaches are
also needed to overcome limited solubility and poor bio-
availability of phenolic acids. These include synthesis of
phenolic acids derivatives and development of novel
drug delivery system and formulations such as nanopar-
ticles, liposomal encapsulation, emulsions, and sustained
released tablets. Therefore, enhanced bioavailability and
convinced clinical trial results of phenolic acids could
bring these promising natural products to the forefront
of therapeutic agents for obesity.
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